AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is conducting a Phase III study titled A Phase III, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Effect of AZD0780 on Low-Density Lipoprotein Cholesterol in Patients With Heterozygous Familial Hypercholesterolaemia. The study aims to evaluate the efficacy and safety of AZD0780, a small molecule designed to reduce LDL-C levels in adults with HeFH.
The intervention being tested is AZD0780, administered as a daily oral dose. It is intended to lower LDL-C levels in patients, with a placebo used for comparison.
This is a randomized, double-blind, placebo-controlled study with a parallel-group design. Participants will be randomly assigned to either the AZD0780 or placebo group, with both participants and investigators unaware of the assignments. The primary purpose is treatment.
The study began on June 10, 2025, with an estimated primary completion date of mid-2026. The last update was submitted on July 22, 2025. These dates are crucial for tracking the study’s progress and anticipated results.
The outcome of this study could significantly impact AstraZeneca’s stock performance and investor sentiment, particularly if AZD0780 proves effective. This development is noteworthy in the competitive landscape of cholesterol-lowering treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.